Drugs / BMS-986308
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04763226 | Apr 2021 → Feb 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986308 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04763226 ↗ |
| Action | Inhibit | “BMS-986308, an oral, selective, reversible renal outer medullary potassium channel (ROMK) inhibitor” PMID 39219444 ↗ Sep 2024 |
| Route | Oral | “BMS-986308, an oral” PMID 39219444 ↗ Sep 2024 |